Fig. 3From: Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancerA novel EML4-MET fusion in a patient who responded to crizotinib treatment. A The treatment timeline of the reported patient harboring the EML4-MET fusion. B CT scan revealed a significant response to crizotinib in the patient harboring the EML4-MET fusionBack to article page